The overlap between anxiety, depression, and obsessive-compulsive disorder

Dialogues in Clinical Neuroscience

Volumn 17, Issue 3, 2015, Pages 249-260

  Goodwin, Guy M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Anxiety; Compulsive disorder; Depression; OCD

Indexed keywords

AGOMELATINE; DOPAMINE RECEPTOR BLOCKING AGENT; GABAERGIC RECEPTOR AFFECTING AGENT; MONOAMINE OXIDASE INHIBITOR; PREGABALIN; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

AGORAPHOBIA; AMYGDALOID NUCLEUS; ANGER; ANHEDONIA; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; COGNITIVE BIAS; COGNITIVE THERAPY; COMORBIDITY; DISGUST; DISTRESS SYNDROME; DIZYGOTIC TWINS; DSM-5; ELECTROPHYSIOLOGY; EMOTIONAL BIAS; ENVIRONMENTAL FACTOR; EVIDENCE BASED PRACTICE; EXCITATORY POSTSYNAPTIC POTENTIAL; FACE TO FACE PSYCHOTHERAPY; FEAR; FIRST DEGREE RELATIVE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE EXPRESSION; GENE FUNCTION; GENERALIZED ANXIETY DISORDER; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; GUILT; HUMAN; INHERITANCE; INTERNET; INTERNET BASED PSYCHOLOGICAL TREATMENT; LONG TERM POTENTIATION; MAJOR DEPRESSION; MONOZYGOTIC TWINS; NEUROBIOLOGY; NEUROIMAGING; OBSESSIVE COMPULSIVE DISORDER; PANIC; PERSONALITY; PHENOTYPE; POSTERIOR INSULA; POSTTRAUMATIC STRESS DISORDER; PSYCHOTHERAPY; SADNESS; SELF HELP; SEPARATION ANXIETY; SOCIAL PHOBIA; ANXIETY; DEPRESSION; GENETICS; MOLECULAR BIOLOGY; OBSESSIVE-COMPULSIVE DISORDER;

ANXIETY; DEPRESSION; HUMANS; MOLECULAR BIOLOGY; NEUROBIOLOGY; NEUROIMAGING; OBSESSIVE-COMPULSIVE DISORDER;

EID: 84945301771     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. th ed. Washington, DC: American Psychiatric Association; 2013.
2. Magee WJ, Eaton WW, Wittchen HU, McGonagle KA, Kessler RC. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry. 1996;53(2):159-168.
3. Crino RD, Andrews G. Obsessive-compulsive disorder and axis I comorbidity. J Anxiety Disord. 1996;10(1):37-46.
4. Kessler RC, Nelson CB, McGonagle KA, Liu J, Swartz M, Blazer DG. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry Suppl. 1996(30):17-30.
5. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Meth Psychiatr Res. 2012;21(3):169-184.
6. Hofmeijer-Sevink MK, Batelaan NM, van Megen HJ, et al. Clinical relevance of comorbidity in anxiety disorders: a report from the Netherlands Study of Depression and Anxiety (NESDA). J Affect Disord. 2012;137(1-3):106-112.
7. Watson D, Tellegen A. Toward a consensual structure of mood. Psychol Bull. 1985;98(2):219-235.
8. Watson D, Wiese D, Vaidya J, Tellegen A. The two general activation systems of affect: Structural findings, evolutionary considerations, and psychobiological evidence. J Personal Soc Psychol. 1999;76(5):820-838.
9. Clark LA, Watson D. Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. J Abnorm Psychol. 1991;100(3):316-336.
10. Kendler KS, Prescott CA, Myers J, Neale MC. The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. Arch Gen Psychiatry. 2003;60(9):929-937.
11. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry. 2001;158(10):1568-1578.
12. Mineka S, Watson DW, Clark LA. Psychopathology: comorbidity of anxiety and unipolar mood disorders. Ann Rev Psychol. 1998;49:377-412.
13. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403-339.
14. Kendler KS, Hettema JM, Butera F, Gardner CO, Prescott CA. Life event dimensions of loss, humiliation, entrapment, and danger in the prediction of onsets of major depression and generalized anxiety. Arch Gen Psychiatry. 2003;60(8):789-796.
15. Hettema JM, Prescott CA, Myers JM, Neale MC, Kendler KS. The structure of genetic and environmental risk factors for anxiety disorders in men and women. Arch Gen Psychiatry. 2005;62(2):182-189.
16. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274(5292):1527-1531.
17. Munafo MR, Freimer NB, Ng W, et al. 5-HTTLPR genotype and anxiety-related personality traits: a meta-analysis and new data. Am J Med Genet B Neuropsychiatr Genet. 2009;150B(2):271-281.
18. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301(5631):386-389.
19. Munafo MR, Flint J. How reliable are scientific studies? Br J Psychiatry. 2010;197(4):257-258.
20. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421-427.
21. Network and Pathway Analysis Subgroup of Psychiatric Genomics Consortium. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat Neurosci. 2015;18(2):199-209.
22. Feinstein JS, Adolphs R, Damasio A, Tranel D. The human amygdala and the induction and experience of fear. Curr Biol. 2011;21(1):34-38.
23. LaBar KS, Gatenby JC, Gore JC, LeDoux JE, Phelps EA. Human amygdala activation during conditioned fear acquisition and extinction: a mixed-trial fMRI study. Neuron. 1998;20(5):937-945.
24. Whalen PJ, Rauch SL, Etcoff NL, McInerney SC, Lee MB, Jenike MA. Masked presentations of emotional facial expressions modulate amygdala activity without explicit knowledge. J Neurosci. 1998;18(1):411-418.
25. Murphy SE, Norbury R, Godlewska BR, et al. The effect of the serotonin transporter polymorphism (5-HTTLPR) on amygdala function: a meta-analysis. Mol Psychiatry. 2013;18(4):512-520.
26. Pergamin-Hight L, Naim R, Bakermans-Kranenburg MJ, van IMH, Bar-Haim Y. Content specificity of attention bias to threat in anxiety disorders: a meta-analysis. Clin Psychol Rev. 2015;35:10-18.
27. Chan SW, Goodwin GM, Harmer CJ. Highly neurotic never-depressed students have negative biases in information processing. Psychol Med. 2007;37(9):1281-1291.
28. Fonzo GA, Ramsawh HJ, Flagan TM, et al. Common and disorderspecific neural responses to emotional faces in generalised anxiety, social anxiety and panic disorders. Br J Psychiatry. 2015;206(3):206-215.
29. Etkin A, Schatzberg AF. Common abnormalities and disorder-specific compensation during implicit regulation of emotional processing in generalized anxiety and major depressive disorders. Am J Psychiatry. 2011;168(9):968-978.
30. Harmer CJ, O'Sullivan U, Favaron E, et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry. 2009;166(10):1178-1184.
31. Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry. 2006;59(9):816-820.
32. Godlewska B, Browning M, Norbury R, Cowen P, Harmer C. Early changes in neural responses to emotional information predict clinical response to antidepressant treatment in depression. Int J Neuropsychopharmacol. 2014;17:82.
33. Reinecke A, Waldenmaier L, Cooper MJ, Harmer CJ. Changes in automatic threat processing precede and predict clinical changes with exposure-based cognitive-behavior therapy for panic disorder. Biol Psychiatry. 2013;73(11):1064-1070.
34. Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(5):561-566.
35. Taylor D, Sparshatt A, Varma S, Olofinjana O. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ. 2014;348:g1888.
36. Stein DJ, Ahokas A, Albarran C, Olivier V, Allgulander C. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry. 2012;73(7):1002-1008.
37. Harmer CJ, de Bodinat C, Dawson GR, et al. Agomelatine facilitates positive versus negative affective processing in healthy volunteer models. J Psychopharmacol. 2011;25(9):1159-1167.
38. Cuijpers P, Donker T, van Straten A, Li J, Andersson G. Is guided self-help as effective as face-to-face psychotherapy for depression and anxiety disorders? A systematic review and meta-analysis of comparative outcome studies. Psychol Med. 2010;40(12):1943-1957.
39. Lewis C, Pearce J, Bisson JI. Efficacy, cost-effectiveness and acceptability of self-help interventions for anxiety disorders: systematic review. Br J Psychiatry. 2012;200(1):15-21.
40. Arnberg FK, Linton SJ, Hultcrantz M, Heintz E, Jonsson U. Internet-delivered psychological treatments for mood and anxiety disorders: a systematic review of their efficacy, safety, and cost-effectiveness. PLoS One. 2014;9(5):e98118.